Insulin device maker Insulet Corporation (NASDAQ:PODD) reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56. It reported an EPS of $0.38 a year ago. The company reported sales of $488.5 million, beating the consensus of $463.31 million, which is in line with the preliminary earnings reported in July. The sales increased 23.2% year over year, or 23.4% in constant currency, exceeding the company’s guidance of 18% due to revenue outperformance for all product lines. Omnipod revenue of $480.4 million, an increase of 26.3% (+26.5% in constant currency) U.S. Omnipod revenue of $352.3 million, an increase of 27.3% International Omnipod revenue of $128.1 million, an increase of 23.5%, or 24.4% in constant currency “We remain the clear leader in our industry, and in light of our first half ...